Was bedeutet ESBL?

Schlüsselwörter

ESBL - Extended-spectrum- Betalaktamase

Keywords

ESBL - extended-spectrum beta-lactamase

• Literatur

• 1 Aldeyab MA, Harbarth S, Vernaz N et al. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol 2012; 74: 171-179
• 2 Balakrishnan I, Awad-El-Kariem FM, Aali A et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2011; 66: 2628-2631
• 3 Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin Ther 2012; 34: 124-137
• 4 Buehlmann M, Bruderer T, Frei R et al. Effectiveness of a new decolonisation regimen for eradication of extended-spectrum β-lactamase-producing Enterobacteriaceae. J Hosp Infect 2011; 77: 113-117
• 5 Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu Rev Microbiol 2011; 65: 455-478
• 6 Campbell JD, Lewis 2nd JS, McElmeel ML et al. Detection of favorable oral cephalosporin-clavulanate interactions by in vitro disk approximation susceptibility testing of extended-spectrum-Beta-lactamase-producing members of the enterobacteriaceae. J Clin Microbiol 2012; 50: 1023-1026
• 7 Geser N, Stephan R, Korczak BM et al. Molecular identification of extended-spectrum-β-lactamase genes from Enterobacteriaceae isolated from healthy human carriers in Switzerland. Antimicrob Agents Chemother 2012; 56: 1609-1612
• 8 Hammerum AM, Lester CH, Jakobsen L et al. Faecal carriage of extended-spectrum β-lactamase-producing and AmpC β-lactamase-producing bacteria among Danish army recruits. Clin Microbiol Infect 2011; 17: 566-568
• 9 López-Cerero L, Picón E, Morillo C et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect 2010; 16: 132-136
• 10 Nicolas-Chanoine MH, Jarlier V, Robert J et al. Patient's origin and lifestyle associated with CTX-M-producing Escherichia coli. PLoS One 2012; 7: e30498
• 11 Oteo J, Bautista V, Lara N et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010; 65: 2459-2463
• 12 Overdevest I, Willemsen I, Rijnsburger M et al. Extended-spectrum β-lactamase genes of Escherichia coli in chicken meat and humans, The Netherlands. Emerg Infect Dis 2011; 17: 1216-1222
• 13 Prasad P, Sun J, Danner RL et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54: 1699-709
• 14 Rodríguez-Baño J, Navarro MD, Retamar P et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli. Clin Infect Dis 2012; 54: 167-174
• 15 Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome. J Antimicrob Chemother 2012; 67: 1311-1320
• 16 Titelman E, Iversen A, Kahlmeter G et al. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS 2011; 119: 853-863